Dogwood Therapeutics Inc DWTX 深 滬
等待開盤 04-30 09:30:00 美东时间
1.35
0.000
0.00%
華盛通- 最 高1.36
- 今 開1.35
- 成交量 7.75万股
- 最 低 1.28
- 昨 收 1.35
- 總市值 4509.21万
- 52周最高 9.50
- 市盈率 靜 --
- 換手率 0.23%
- 52周最低 1.28
- 委 比 91.26%
- 總股本 3340.16万
- 歷史最高 417.75
- 量 比 0.48
- 振 幅 5.93%
- 歷史最低 1.28
- 每 手 1
- 風險率 1.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美银大幅上调西部数据、希捷科技目标价！宝洁、Baker Hughes、Flagstar Bank、斯伦贝谢等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从48美元升至49美元；Chardan Capital：维持Intellia Therapeutics"买入"评级，目标价从27美元升至30美元
04-28 10:07
Dogwood Therapeutics Partners With PRIDCor Therapeutics To Advance Its Anti-Viral Candidates IMC-1 And IMC-2
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing new medicines to treat pain and neuropathy, today announced a global development and commercialization
04-23 21:07
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Psyence Biomedical (NASDAQ:PBM) shares increased by 63.4% to $9.59 dur...
04-17 05:05
Dogwood Therapeutics Announces FDA Acceptance Of IND Application For Development Candidate SP16, Administered IV, For Treatment Of Chemotherapy-Induced Pain And Peripheral Neuropathy
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin PharmaThe SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in
04-15 21:08
Dogwood Therapeutics Q4 net loss narrows on lower expenses
Dogwood Therapeutics Q4 net loss narrows on lower expenses Overview US biotechnology developer's Q4 net loss narrowed yr/yr due to lower administrative expenses Full year net loss widened, driven by increased R&D expenses for clinical trials and licensing Company completed $26.9 mln financing in Jan
03-18 20:38
Dogwood Therapeutics Q4 EPS $(0.26) Beats $(1.17) Estimate
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(1.17) by 77.83 percent. This is a 95.87 percent increase over losses of $(6.29) per share
03-18 20:34
Dogwood Therapeutics FY2025 net loss attributable to common stockholders widens to USD 35.51 million as R&D spending rises more than sixfold to USD 21.87 million
Dogwood Therapeutics FY2025 net loss attributable to common stockholders widens to USD 35.51 million as R&D spending rises more than sixfold to USD 21.87 million Dogwood Therapeutics published a press release reporting Q4 and full-year 2025 financial results. Q4 net loss attributable to common stock
03-18 20:32
美股大行评级 | 苹果、SanDisk、西部数据、卡特彼勒、德克斯户外、霍尼韦尔、西南航空、万事达等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Praxis Precision Medicine"买入"评级，目标价从340美元升至1245美元；HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从10美元升至12美元
02-02 14:15
HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
01-30 19:26
Dogwood Therapeutics Highlights Pipeline Expansion And Clinical Progress Toward Non-Opioid Cancer Pain And Neuropathy Treatments; Key Halneuron And SP16 Milestones Targeted For 2026
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("DWTX" or "Company"), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, issues a corporate update in the following Letter to
01-20 21:37
